Oral GLP-1 Drug Orforglipron Improves Heart Disease Risk Markers in Diabetes and Obesity

Orforglipron produced significant placebo-adjusted decreases in blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP in both the T2D study (N=361, 26 weeks) and the obesity study (N=234, 36 weeks). Improvements in CV risk markers at 12 mg were of similar magnitude to those seen at 24, 36, and 45 mg doses, suggesting a plateau effect for cardiovascular benefits. The improvements were consistent across both populations — people with type 2 diabetes and people with obesity alone — indicating the cardiovascular benefits are not limited to diabetic patients.

Exploratory analysis of cardiovascular risk biomarkers from two phase 2 randomized controlled trials. The T2D study (NCT05048719) randomized 361 participants (mean age 59, mean BMI 35.3, mean HbA1c 8.1%) to orforglipron 3-45 mg daily, dulaglutide 1.5 mg weekly, or placebo for 26 weeks. The obesity study (NCT05051579) randomized 234 participants (mean age 54, mean BMI 37.9) to orforglipron 12-45 mg daily or placebo for 36 weeks. Blood pressure, lipids, ApoB, ApoC3, NT-pro-BNP, hsCRP, and IL-6 were measured at baseline and endpoint.

Current GLP-1 drugs like semaglutide require injections, which many patients avoid. Orforglipron as a daily pill could dramatically expand access to GLP-1 therapy. Showing cardiovascular risk reduction — on top of weight loss and blood sugar control — strengthens the case for orforglipron as a comprehensive cardiometabolic treatment.

The oral GLP-1 race is one of the biggest stories in pharmaceutical development. With injectable semaglutide (Ozempic/Wegovy) already showing cardiovascular event reduction in large outcome trials, demonstrating that the oral candidate orforglipron improves the same risk markers is a critical stepping stone toward potential cardiovascular outcome trial success.

This was an exploratory post-hoc analysis of phase 2 trial data, not a dedicated cardiovascular outcome trial. The studies were not powered to detect differences in actual cardiovascular events like heart attacks or strokes. Follow-up was relatively short (26-36 weeks). Specific numeric improvements for each biomarker were not detailed in the abstract. Phase 3 cardiovascular outcome trials are needed to confirm clinical benefit.